Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$43.97 USD
+0.74 (1.71%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $43.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TNDM 43.97 +0.74(1.71%)
Will TNDM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TNDM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TNDM
Here's How Thermo Fisher (TMO) is Placed Ahead of Q2 Earnings
Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings?
TNDM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi
Other News for TNDM
Healthcare 2024 Second Half Outlook
Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024
What's Driving Tandem Diabetes Care Inc's Surprising 15% Stock Rally?
Buy Rating Affirmed: Tandem Diabetes Care’s Innovative Edge and Strategic Growth Outlook
Tandem Diabetes, DexCom see weakness following ADA conference